Scan: Will Trump make IVF free?

← Back to scans

Will Trump make IVF free? — Before 2029

KXFREEIVF-29 · Health · 2026-05-13

13%

Agent

14%

Market Price

-1.0%

Edge

60%

Confidence

Volume: 34,421

Spread: 1.0c

Days to resolution: 982

Markets in event: 1

Final Rationale

My independent estimate of 10.3% was driven by strong negative signals: the Feb 2025 EO produced only study/voluntary recommendations, the White House explicitly rejected insurer mandates in Aug 2025, the NDAA IVF provision was stripped in Dec 2025, and the administration's pivot to TrumpRx discounts and voluntary employer guidance suggests a ceiling well short of 'free.' I PARTIALLY ACCEPT the critique's points on combination math and asymmetric evidence — disjunctive combination of three paths (4%, 5%, 13%) should not yield a number below the highest single path, and resolution ambiguity around 'at least one cycle' for a narrow population (FEHB, Medicaid demo, or fully-subsidized TrumpRx pathway) creates a wider YES surface than I credited. I REJECT the temporal uncertainty challenge as warranting a larger move — administration positioning has been consistent across 15+ months and the binding constraint (pro-life GOP + 60-vote Senate) is structural. The market at 14% with thin volume and heavy NO-side depth is consistent with my revised estimate of 13%, so I converge close to market while retaining a small downward tilt based on the specific negative policy signals.

Price vs. prediction

How the market moved after the agent's call. Solid blue line is the actual market price; dashed line is the agent's static forecast at $t{=}0$.

$n = 58$ follow-ups

Re-scan Context

This market has been scanned before. Previous predictions:

Date	Predicted	Market Price	Confidence
2026-05-06	12%	17%	62%
2026-04-29	14%	16%	50%
2026-04-03	10%	16%	50%

1. Planner Opus · Fermi decomposition + tool plan

Tools chosen: kalshi_data kalshi_orderbook article_search web_search congress_bills

Sub-questions (Fermi decomposition)

Has Trump already taken or announced a specific executive action to make IVF free or fully subsidized as of May 2026? (w=0.25)
Will Congress pass legislation that Trump signs making at least one IVF cycle free before January 2029? (w=0.35)
Will Trump issue an executive order or use regulatory authority (e.g., directing insurers, Medicare/Medicaid) to eliminate the cost of at least one IVF cycle before January 2029? (w=0.40)

Planner reasoning

This question asks whether Trump will eliminate the cost of at least one IVF cycle before January 20, 2029 — a bold campaign promise requiring either legislative action or executive/regulatory authority. Key reference classes and mechanisms: 1. **Campaign promise fulfillment**: Trump explicitly promised to make IVF free (either government-paid or insurance-mandated) during the 2024 campaign. However, campaign promises on complex policy areas have highly variable fulfillment rates. Healthcare mandates face constitutional and industry resistance. 2. **Legislative path**: A bill requiring insurers to cover IVF or creating federal subsidies would need to pass Congress. With a Republican majority that has pro-life factions skeptical of IVF (following the Alabama Supreme Court embryo ruling controversy), this is politically contentious even within the GOP. The Senate's 60-vote threshold for most legislation is a major hurdle. 3. **Executive/regulatory path**: Trump could potentially use executive orders to direct federal employee health plans (FEHB) to cover IVF, or use HHS/CMS rulemaking to require coverage under ACA marketplace plans or Medicaid. The FEHB path is narrower (only covers federal employees) but more legally straightforward. ACA mandate changes face legal challenges. 4. **Temporal dynamics**: With 982 days remaining (until Jan 20, 2029), there's substantial time left, but the window is narrowing. The first term analogy: Trump made similar promises about healthcare in 2017 that failed. However, IVF has broader bipartisan sympathy post-Dobbs, and the political incentive to deliver on this specific promise is high given its salience to suburban women voters. 5. **'Free' threshold**: The resolution requires eliminating cost of 'at least one IVF cycle' — this is a lower bar than making all IVF free. An executive order covering federal employees or a narrow insurance mandate could meet this threshold. The critical path to YES: Trump issues an executive order or signs legislation (likely by mid-2027 to allow implementation before Jan 2029). The realistic sequence involves: (a) White House develops policy proposal, (b) either EO drafted or bill introduced in Congress, (c) passage/signing, (d) implementation begins. Each step has meaningful probability of stalling. Base rate consideration: Major healthcare coverage expansions that are politically popular but face industry resistance historically have ~15-30% passage rates in comparable timeframes. The unique factor here is Trump's personal commitment and the political calculus post-Dobbs.

2. Research Parallel tool calls · legacy v2

Tool	Status	Time	Items
kalshi_data	OK	2.1s	-
kalshi_orderbook	OK	0.2s	-
article_search	OK	1.0s	-
web_search	OK	72.9s	-
congress_bills	OK	0.7s	-

3. Evidence Synthesis Sonnet · 14 items · legacy v2

#	Strength	Credibility	Direction	Source	Claim	Priced In
1	STRONG	88	↓ DOWN	article_search	In February 2025, Trump signed an executive order directing policy recommendations on IVF access and cost reduction, but the EO itself does not create binding regulation or make IVF free.	Yes
2	STRONG	90	↓ DOWN	article_search	On October 16, 2025, the White House announced guidance encouraging (not requiring) employers to offer fertility benefits, and a drug pricing deal with EMD Serono for up to 84% discounts on IVF medications via TrumpRx — not eliminating IVF costs.	Yes
3	STRONG	82	↓ DOWN	article_search	As of August 2025, the White House had no plan to mandate IVF insurance coverage despite Trump's campaign promise, according to two people with knowledge of internal discussions.	Yes
4	MODERATE	78	↓ DOWN	web_search	TrumpRx.gov launched on February 5, 2026 with reduced fertility drug pricing, but this reduces costs rather than eliminating them; it does not constitute making IVF 'free'.	Yes
5	MODERATE	72	NEUTRAL	web_search	On May 10, 2026, the Trump administration announced a proposed rule (Labor Department) aimed at making it easier for employers to offer IVF services — still voluntary/facilitative, not mandating free IVF.	No
6	MODERATE	75	↓ DOWN	congress_bills	No IVF-specific legislation appears in the congressional bills data; the bills returned are entirely unrelated to IVF or fertility coverage mandates.	Yes
7	STRONG	82	↓ DOWN	article_search	The White House explicitly ruled out requiring insurers to cover IVF as of August 2025, significantly reducing the likelihood of administration-backed legislation mandating free IVF.	Yes
8	MODERATE	78	↓ DOWN	article_search	Action on IVF coverage is occurring at the state level (Tennessee, Virginia, California, Georgia) rather than through Congress, suggesting the legislative path at the federal level remains stalled.	Yes
9	STRONG	90	↓ DOWN	article_search	The October 2025 White House IVF announcements explicitly stated the government would NOT provide subsidies or require coverage — only voluntary employer guidance and drug discounts, falling far short of making IVF free.	Yes
10	MODERATE	70	↓ DOWN	web_search	The May 10, 2026 proposed Labor Department rule focuses on facilitating voluntary employer IVF benefit offerings — not directing insurers, Medicare, or Medicaid to cover IVF at no cost.	No
11	STRONG	85	↓ DOWN	article_search	Trump's February 2025 EO directed policy recommendations but explicitly lacked binding regulatory authority; agency implementation depends on statutory authority under ERISA, ACA, and IRC.	Yes
12	STRONG	83	↓ DOWN	article_search	The IVF policy deadline set in the February 2025 EO (May 2025) passed with no substantive mandate announced, indicating slow and limited regulatory follow-through.	Yes
13	MODERATE	65	↓ DOWN	kalshi_data	The Kalshi prediction market prices 'Will Trump make IVF free before 2029' at 14%, down 1% over 7 days and up 2% over 30 days, with a wide historical range of 9-39%.	Yes
14	MODERATE	60	↓ DOWN	kalshi_orderbook	The orderbook shows a $0.98 spread between yes and no bids with very high depth (26,205), suggesting extreme illiquidity on the yes side and strong market conviction that resolution is unlikely.	Yes

Information Gaps

No data on whether the May 10, 2026 proposed Labor Department rule includes any mandatory coverage provisions or cost elimination mechanisms — the web search summary was cut off before full details were provided.
No information on whether any IVF-specific federal legislation has been introduced in Congress (the bills search returned completely unrelated results).
No data on the current status of FEHB (Federal Employee Health Benefits) coverage of IVF — an executive directive to FEHB could be a legally feasible narrow path to meeting the 'free for at least one cycle' threshold.
No information on whether the administration has explored Medicaid or Medicare rulemaking pathways for IVF coverage.
No data on internal White House deliberations in 2026 regarding IVF policy beyond the May 10 proposed rule announcement.
Missing: whether the TrumpRx drug discounts plus any procedure subsidies could collectively eliminate patient cost for at least one cycle for any population segment.
No polling or political pressure data from 2026 on IVF as an electoral issue ahead of midterms.

Key Uncertainties

Whether the May 2026 proposed Labor Department rule contains any mandatory IVF coverage provisions that could constitute 'free' access for at least one cycle.
Whether Trump's political calculus shifts heading into 2026 midterms, potentially creating pressure to deliver a more substantive IVF action.
The legal feasibility and administration willingness to use FEHB authority to mandate IVF coverage for federal employees — a narrower but cleaner executive path.
Whether 'free' can be interpreted broadly enough (e.g., zero net cost to patient combining insurance + drug discounts) that some combination of existing actions qualifies.
Whether a standalone IVF bill could attract bipartisan Senate support to overcome the 60-vote filibuster threshold.
The impact of pro-life Republican factions on any legislative or regulatory IVF mandate.
Whether the administration's apparent pivot from mandates to voluntary facilitation (October 2025 announcements) represents a permanent policy ceiling or a tactical retreat before election pressure.

Market Context

Price: 0.14 · 7d: -0.01 · 30d: +0.02
Volume: LOW — 143 contracts/day average, thin market · Depth: VERY SKEWED — $0.98 spread with heavy depth on NO side (26,205 total depth) indicating near-consensus that resolution is unlikely; yes-side liquidity essentially absent
Reliability: LOW-MEDIUM — Low volume limits price discovery quality; extreme orderbook imbalance may reflect true low probability but could also reflect market neglect; historical range of 9-39% shows significant past uncertainty

4. Independent Forecaster Opus · No market price · legacy v2 Did NOT see market price

Independent estimate: 10% (63% confidence)

base rate

10%

62% conf

evidence driven

10%

66% conf

contrarian

11%

60% conf

Spread

1pp

Low disagreement

sq1: Has Trump already taken or announced a specific executive action to make IVF free or fully subsidized as of May 2026?

All actions to date (Feb 2025 EO for recommendations, Oct 2025 voluntary guidance, TrumpRx drug discounts, May 2026 proposed facilitation rule) reduce costs but do not eliminate them. Administration explicitly ruled out mandates. Base rate for 'already happened but ambiguous' is low. ~4%.

sq2: Will Congress pass legislation that Trump signs making at least one IVF cycle free before January 2029?

Base rate for novel healthcare mandates passing 60-vote Senate threshold in ~2.5 years is ~5-10%. No IVF bill is moving, NDAA IVF provision was stripped in Dec 2025, White House opposes mandates, pro-life GOP faction resists. Pushes well below base rate to ~5%.

sq3: Will Trump issue an executive order or use regulatory authority to eliminate the cost of at least one IVF cycle before January 2029?

13%

Administration has pivoted explicitly to voluntary/facilitative approach. However, midterm pressure in 2026 and 2028 election cycle could create incentive for a narrow action (FEHB mandate, Medicaid demonstration, or expanded TrumpRx subsidy that zeroes out one cycle). The 'at least one cycle' threshold is relatively low and could potentially be met by a narrow federal employee action. Trump has shown willingness to use aggressive EO authority. ~13%.

Show full reasoning trace

base rate: Major healthcare coverage expansions facing industry/intra-party resistance pass at ~15-25% rates over 4-year terms. However, base rate for fulfilling specific bold campaign healthcare promises is lower (~10-20%), and Trump's first-term healthcare track record (ACA repeal failure) suggests lower end.

evidence updates: Multiple strong negative signals: (1) Feb 2025 EO was study-only and the May 2025 deadline passed without mandate, (2) Aug 2025 explicit White House statement against insurer mandates, (3) Oct 2025 pivot to voluntary employer guidance + drug discounts, (4) Dec 2025 NDAA IVF provision stripped, (5) May 2026 proposed rule remains facilitative not mandatory. Each pushes probability down from base rate. Upward pressure only from: midterm/2028 political incentives and possible narrow FEHB path.

combination method: Weighted average across three paths (existing action, legislation, future regulatory action). Slight upward adjustment for resolution ambiguity and correlated paths.

final: Independent estimate ~10%. Strong evidence of administration ceiling at voluntary/discount approaches, but ~2.5 years remain with potential political pressure to deliver. Final: 10%.

ensemble: {'ensemble_count': 3, 'perspectives': {'base_rate': {'p_yes': 0.1, 'confidence': 0.62}, 'evidence_driven': {'p_yes': 0.1, 'confidence': 0.66}, 'contrarian': {'p_yes': 0.11, 'confidence': 0.6}}, 'spread': 0.01, 'individual_p_yes': {'base_rate': 0.1, 'evidence_driven': 0.1, 'contrarian': 0.11}}

5. Devil's Advocate Sonnet · legacy v2 Market price revealed

Asymmetric Evidence Reasoning Flaw

Challenges

The resolution criterion 'make IVF free' is ambiguous and the forecaster may be interpreting it too strictly. Does 'free' require zero-cost to ALL patients, or 'free for at least one cycle' for some population (e.g., FEHB enrollees, military, Medicaid demonstration)? The sq3 acknowledges this ambiguity but the final 10% may not adequately price in the resolution risk that a narrow action could be plausibly graded YES by a generous resolver, especially given Trump's tendency toward declarative claims of victory.
The evidence balance (0 UP, 13 DOWN, 1 NEUTRAL) looks suspiciously one-sided. The forecaster collected almost no upside evidence — e.g., no investigation of FEHB pathway, Medicaid demonstration authority, or whether TrumpRx + subsidies could zero out cost for some subset. This asymmetric evidence collection may have biased the estimate downward. The information gaps section confirms several unexplored upside paths.
With 982 days (~2.7 years) to resolution, there is substantial time for political pressure to shift policy (2026 midterms, 2028 election positioning). The forecaster acknowledges this but the evidence-driven downward updates are based on a snapshot of administration policy as of May 2026 — administration positioning can pivot dramatically, especially Trump's. The confidence (0.627) may be too high given this temporal uncertainty.
The forecaster treats the three sub-questions as somewhat independent paths but the combination method ('weighted average ... slight upward adjustment') is vague. A proper disjunctive combination of 0.04, 0.05, 0.13 (treating as independent) yields ~0.20, while the lowest plausible (max) is 0.13. The final 0.10 is below even the highest single path, which is mathematically suspect unless the paths are highly correlated downward.

Suggested adjustment: +3pp

Modest upward adjustment warranted because: (1) the combined probability of 0.10 is lower than the highest single-path probability (sq3 = 0.13), which is mathematically inconsistent for paths that are not perfectly correlated; (2) evidence collection was notably asymmetric (0 UP signals) suggesting confirmation bias against upside scenarios; (3) resolution ambiguity ('at least one cycle free for some population') creates a wider YES surface than the forecaster credits. This adjustment is NOT toward the market — the market at 14% happens to be in a similar range, but the reasoning flaws independently justify a small upward move.

Market comparison: Forecaster: 10.3%, Market: 14%. The 3.7pp divergence is modest and within reasonable disagreement range. The market is thin (143 contracts/day) with heavy NO-side depth, suggesting the market and forecaster largely agree directionally. The divergence is not large enough to demand reconciliation, but the forecaster's combination math flaw and asymmetric evidence collection independently suggest a small upward adjustment is warranted.

6. Aggregator Opus · final calibrated forecast

13% (60% confidence)